Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease
- Substances:GolimumabGuselkumab
Austria- Participants:18–64 years · 65+ years
- Substances:Golimumab
Rare diseases
Investigational molecules
Locations
AustriaEfficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis
AustriaA Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease
AustriaOne-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease
FranceStudy of guselkumab and dietary changes for patients with recurring or difficult-to-treat pouchitis
BelgiumStudy on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn's Disease
AustriaStudy on Proactive Drug Monitoring with Secukinumab, Ixekizumab, or Guselkumab for Patients with Moderate-to-Severe Psoriasis
BelgiumStudy on the Effect of Guselkumab for Treating Enthesitis in Patients with Psoriatic Arthritis Who Have Not Used Biologic DMARDs
GermanyStudy on the Long-term Safety of Guselkumab for Children with Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis
BelgiumStudy on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol
GermanyStudy on Preventing Crohn's Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk
BelgiumA Study of Guselkumab and Ciclosporin in Patients with Early Psoriatic Arthritis Transitioning from Skin to Joint Disease
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.